title: Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.
abstract: Influenza A(H5N1) vaccination strategies that improve the speed of the immunological response and cross-clade protection are desired. We compared the immunogenicity of a single 15-μg or 90-μg dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine in adults who were previously primed with A/H5N1/Vietnam/1203/2004 (clade 1) vaccine. High-dose vaccine resulted in significantly higher titers to both clade 1 and 2 antigens. Clade 2 titers were unaffected by the previous dose of clade 1 vaccine. Low-dose priming with a mismatched pandemic influenza A(H5N1) vaccine would improve the rapidity, magnitude, and cross-reactivity of the immunological response following a single high-dose, unadjuvanted, pandemic vaccine.
authors.affiliation: Department of Internal Medicine, University of Iowa and Iowa City VA Healthcare System.
authors.forename: Patricia L
authors.initials: PL
authors.lastname: Winokur
authors.affiliation: Department of Medicine Department of Molecular Virology, and Microbiology, Baylor College of Medicine, Houston, Texas.
authors.forename: Shital M
authors.initials: SM
authors.lastname: Patel
authors.affiliation: Gamble Program for Clinical Studies, Cincinnati Children's Hospital, Ohio.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Brady
authors.affiliation: Center for Vaccine Development, University of Maryland School of Medicine, Baltimore.
authors.forename: Wilbur H
authors.initials: WH
authors.lastname: Chen
authors.affiliation: Center for Vaccine Development, University of Maryland School of Medicine, Baltimore.
authors.forename: Samer S
authors.initials: SS
authors.lastname: El-Kamary
authors.affiliation: Department of Pediatrics, Vanderbilt University, Nashville, Tennessee.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Edwards
authors.affiliation: Department of Pediatrics, Vanderbilt University, Nashville, Tennessee.
authors.forename: C Buddy
authors.initials: CB
authors.lastname: Creech
authors.affiliation: Department of Internal Medicine, Saint Louis University, Missouri.
authors.forename: Sharon
authors.initials: S
authors.lastname: Frey
authors.affiliation: Department of Molecular Virology, and Microbiology, Baylor College of Medicine, Houston, Texas.
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Keitel
authors.affiliation: Department of Internal Medicine, Saint Louis University, Missouri.
authors.forename: Robert
authors.initials: R
authors.lastname: Belshe
authors.affiliation: Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Walter
authors.affiliation: EMMES Corporation, Rockville, Maryland.
authors.forename: Abbie
authors.initials: A
authors.lastname: Bellamy
authors.affiliation: EMMES Corporation, Rockville, Maryland.
authors.forename: Heather
authors.initials: H
authors.lastname: Hill
mesh_terms: D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D003429:Cross Reactions; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D053124:Influenza A Virus, H5N1 Subtype / Q000145:classification / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated
keywords: H5N1; influenza; prime-boost; vaccine